IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy.
Biodegradable dextran microspheres (MS) were developed as a slow-release system for interleukin-2 (IL-2) to apply them for local IL-2 therapy of cancer. We describe the tissue reactions induced by these MS without or with IL-2 in rats. Dextran MS stain bright red-purple with the periodic acid Schiff (PAS), visualising the exact spot of IL-2 release and its relation to the histological reaction pattern. Subcutaneously injected MS always form a well-circumscribed deposit. In the first 2 days there is a PMN inflammation within the MS-deposit, but the surroundings show only a scanty inflammatory reaction. The PMN reaction is replaced by an abundant macrophage reaction in particular in the MS-deposit. At day 21 a fibrous capsule of about 50 mum surrounds the deposit. The effect of IL-2 administered in its free form is mainly vascular, with vascular dilatation, vascular leakage and oedema. It is remarkable that lymphocytes are present in the injection area already at day 2. When IL-2 releasing MS were used, the various reactions induced by IL-2 and MS were amplified leading to local necrosis. We conclude that neither placebo MS nor IL-2 leads to necrosis after subcutaneous injection in rats. In contrast, when IL-2 was released from MS, then massive necrosis was induced. This might be due to increased phagocytosis or changes in the micro-niche due to the release of humoral factors by the infiltrating cells. This is probably fortuitous for local IL-2 therapy of cancer, as massive necrosis of tumour cells can be expected to lead to an increased antitumour reaction.
Department of Cell Biology and Histology, Faculty of Veterinary Medicine, P.O. Box 80.176, 3508 TD Utrecht, The Netherlands.
J W
JW
Koten
M J A
MJ
Van Luyn
J A
JA
Cadée
L
L
Brouwer
W E
WE
Hennink
C
C
Bijleveld
W
W
Den Otter
D000818:Animals; D001672:Biocompatible Materials; D002214:Capsules; D003911:Dextrans / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D004337:Drug Carriers / Q000008:administration & dosage* / Q000737:chemistry; D004487:Edema / Q000139:chemically induced; D004727:Endothelium / Q000187:drug effects / Q000473:pathology; D007279:Injections, Subcutaneous; D007376:Interleukin-2 / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D008214:Lymphocytes / Q000187:drug effects; D008863:Microspheres; D009336:Necrosis; D009369:Neoplasms / Q000188:drug therapy; D018919:Neovascularization, Physiologic / Q000187:drug effects; D010587:Phagocytosis / Q000187:drug effects; D051381:Rats; D012394:Rosaniline Dyes / Q000032:analysis; D040521:Subcutaneous Tissue / Q000098:blood supply / Q000187:drug effects* / Q000473:pathology*; D013997:Time Factors
D001672:Biocompatible Materials; D002214:Capsules; D003911:Dextrans; D004337:Drug Carriers; D007376:Interleukin-2; D012394:Rosaniline Dyes; C476677:Schiff's reagent